IDT Australia Limited · ASX:IDT
IDT Australia — H1 FY2022 Earnings Presentation
8 slides from IDT Australia's earnings presentation, Feb 23, 2022
Slide 1: 2022 Interim Results and Investor Update
IDT AUSTRALIA LIMITED 2022 INTERIM RESULTS AND INVESTOR UPDATE FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 23 February 2022
Slide 2: Key Operational Highlights
Key Operational Highlights IDT Maintaining Profitability, Strong Cash Balance H1 FY`22: Revenue year-on-year increase of 74% to $8.56 million, EBITDA of $1.97 million and $1.21 million Profit H1 FY`22 closing cash balance of $13.31 million Sterile Manufacturing Licence Secured From The Therapeut
Slide 3: Key Financial Highlights
Key Financial Highlights Strong cash balance of $13.31 million Half Year ended 31 December (‘$000) 2021 2020 Variance Year-on-year Revenue increase of 74% to $8.56 million Positive EBITDA of $1.97 million achieved for the half Revenue 8,559 4,911 3,648 74% year $1.21 million Profit for the half year
Slide 4: Sterile Manufacturing: Australia's First cGMP mRNA Drug Product
Sterile Manufacturing: Australia’s First cGMP mRNA Drug Product During the Half Year in review IDT engaged with the Therapeutic Goods Administration (TGA) to successfully deliver the Sterile Readiness Letter Agreement finalised with the Australian Government, Department of Health A Sterile Manuf
Slide 5: Sovereign Manufacturing
Sovereign Manufacturing Approach-To-Market Bid Unsuccessful Modern Manufacturing Initiative Bids Remain Live IDT put forward its existing and licenced sterile manufacturing facility in support of a submission to the Australian Government’s Onshore mRNA Manufacturing Capability: Approach To Market
Slide 6: Medicinal Cannabis
Medicinal Cannabis IDT making further progress executing on its Medicinal Cannabis Manufacturing Plan IDT continues to progress the cGMP development of a range of proprietary medicinal cannabis active pharmaceutical ingredient and finished dosage form products Stability programs ongoing for IDT’
Slide 7: IDT Australia Limited Board and Executive Team
IDT Australia Limited Board of Directors Executive Team Mr Alan Fisher Chair Dr David Sparling CEO Experienced corporate advisor and public company director with a proven More than 20 years of pharma and diagnostics experience in CEO, Director and track record of implementing strategies that enhance
Slide 8: Disclaimer
DISCLAIMER This presentation contains forward looking statements which involve known and unknown risks. By their nature, forward looking statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors which could cause actualresults and devel